A Standout Year for One Health
One Health Group has just delivered a financial performance that demands attention. Their FY2025 results aren’t just solid – they’re explosive, demonstrating how effectively this NHS partner is capitalising on structural healthcare demands. With patient waiting lists dominating political discourse and an ageing population increasing pressure on services, One Health’s model of delivering community-based NHS procedures through independent providers looks increasingly vital. These figures suggest they’re not just participating in the solution – they’re leading it.
The numbers reveal a business firing on all cylinders. Let’s break down the essentials:
Revenue & Profitability
- Turnover: £28.4 million, up 23% from £23.0 million in FY24. Organic growth at this scale in healthcare services is seriously impressive.
- Underlying EBITDA: £2.02 million, a robust 33% increase year-on-year. This shows operational leverage kicking in as scale builds.
- EPS Surge: The real headline grabber – underlying adjusted earnings per share rocketed 185% to 13.75p. When a company more than doubles its EPS, investors rightly sit up.
Cash & Returns to Shareholders
- War Chest: Year-end cash sits at £11.4 million (including £1.2m in an Employee Benefit Trust), massively boosted from £4.7 million last year. That liquidity stems from March’s successful AIM listing, raising £7.8 million.
- Dividend Commitment: A final dividend of 4.13p per share is proposed, taking the total FY25 payout to 6.20p per share. Crucially, dividend cover stands at a healthy 2.2x – signalling sustainability alongside growth ambitions.
Operational Momentum: More Patients, More Capacity
Behind these financials lies remarkable operational execution:
- Patient Demand Surging: New NHS referrals jumped 28% to 17,020. Total consultations hit 42,238 (+25%), and surgical procedures delivered reached 7,043 (+14%). This isn’t just growth; it’s accelerating growth.
- Expanding the Roster: The consultant network grew 27% to 80 specialists, and services now include Urology alongside Orthopaedics, Spine, General Surgery, and Gynaecology.
- Strategic Contracting: Securing 5-year deals with major NHS commissioners (covering ~70% of revenue) is a masterstroke. It replaces volatile annual renewals with predictable, derisked income streams.
- NHS Partnership Deepening: Supporting six NHS Trusts with waiting list reductions (contributing 10% of revenue) proves their model directly alleviates NHS pressure points. The new NHS/Independent Sector agreement (Jan 2025) further validates their role.
The Surgical Hub Strategy: Building the Future
This is where it gets truly strategic. That £11.4 million cash pile isn’t sitting idle:
- First Hub Underway: Land purchased in Northern England, full planning application submitted. Construction expected H1 2025/26, aiming for operational capacity in 2026. This hub targets underserved areas, directly addressing geographic gaps in NHS provision.
- Second Hub in Sight: Actively exploring locations for hub number two. This isn’t a one-off; it’s the blueprint for scalable, owned infrastructure.
CEO Adam Binns nails the vision: “…a key part of our mid to long term growth strategy to deliver strategic surgical capacity growth in underserved areas.” They’re moving beyond just utilising others’ hospitals to building their own dedicated NHS-focused surgical centres.
Leadership Outlook: Confident & Forward-Looking
The tone from Chairman Derek Bickstaff and CEO Adam Binns is unequivocally positive:
- Drivers Aligned: Binns highlights growth across “three drivers: more patients, more operating theatre capacity and a record number of new surgeons.”
- Market Tailwinds: The government’s focus on reducing NHS waiting lists and the explicit agreement to utilise independent sector capacity (Jan 2025) creates a powerful policy backdrop. Bickstaff notes: “Our strategy… is consistent with government policy.”
- Q1 Momentum: Crucially, they confirm strong trading continues post-period-end. This isn’t a one-off spike.
Binns’ closing remark sums up the bullish sentiment: “We look forward to the future with confidence… providing more care to more patients through ‘Patient Choice’ across an ever-increasing geography.”
The Investment Case: More Than Just a Spike
One Health’s FY2025 is a watershed moment. That 185% EPS surge is eye-catching, but it’s the foundation beneath that impresses:
- Scalability Proven: They’re demonstrating consistent organic growth in referrals, consultants, and procedures.
- Infrastructure Investment: Surgical hubs represent a transformative step, promising higher margins and control over capacity.
- Policy Alignment: They’re operating squarely within NHS strategic priorities (waiting lists, patient choice, community care).
- Financial Strength: Significant cash reserves fund growth without jeopardising shareholder returns (evidenced by the maintained dividend).
This isn’t just a good year; it’s evidence of a business model hitting its stride within a structurally supportive market. The challenge now is execution – delivering those hubs and maintaining operational excellence as they scale. Based on this performance, they’ve earned the market’s confidence. The next phase of One Health’s growth story looks compelling.
